Teva offers EU concessions over Allergan generics deal
By Foo Yun Chee BRUSSELS (Reuters) – Teva Pharmaceutical Industries Ltd has offered concessions to allay EU antitrust concerns over its $40.5 billion bid for Allergan's generics unit which will cement its position as the world&039;s largest generics drugmaker. "Commitments have been submitted and the new legal deadline is set on 10 March," European Commission spokesman Ricardo Cardoso said in an email on Friday, without providing details. Teva also declined to provide details.
